Atopic Dermatitis

At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.

Objective tools like IGA and EASI provide structured severity assessment but often lack patient-reported insights such as itch severity.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.

Professor Diamant Thaçi, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumab’s rapid efficacy in treating atopic dermatitis and prurigo nodularis.

A PDUFA target action date has been set for October 13, 2025.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a female patient aged 12 years with moderate AD that had been worsening over the past several months.

Lead author on recent research, Lawrence Eichenfield, MD, said if approved, this treatment could fill a “significant gap.”

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a woman aged 25 years who presented with erythematous and scaly patches on her face, neck, and upper trunk.

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.

The panelist discusses how a 35-year-old man with atopic dermatitis requires personalized, comprehensive management considering skin of color complexities, focusing on trigger identification, targeted therapies like dupilumab, and holistic approach to inflammation, skin barrier protection, and aesthetic concerns.

Panelists discuss the unique challenges of managing atopic dermatitis in children compared with adults, focusing on factors such as skin barrier differences, treatment adherence, and the impact on growth and development.

The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy. Treatment goals include reducing inflammation, improving quality of life, and providing age-appropriate, empathetic care while addressing patient and caregiver concerns about efficacy and safety.

Panelists discuss the mental and physical burden of atopic dermatitis on pediatric patients and their caregivers and share approaches to addressing the psychosocial impact of the condition, highlighting how these factors influence treatment selection and care strategies.

The article highlights the immense global burden of atopic dermatitis, the most common chronic inflammatory skin disease, affecting over 200 million individuals worldwide.

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.